TH
Themis Medicare Ltd (THEMISMED)
₹94.87
Mkt cap
₹929 Cr
P/E ratio
—
P/B
2.19
Div yield
0.50%
ROE
0.41%
ROCE
2.74%
EPS (TTM)
—
Book value
₹43
52W range
65–141
Sector
Healthcare
Price history
Previous close
Incorporated in 1969, Themis Medicare manufactures Formulation and API pharmaceutical products [1]
NSE THEMISMEDBSE 530199
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−32.52% from high₹95
₹65+46.07% from low₹141
Current
₹94.87
Prev close
₹96.98
Day
−2.18%
Price performance
1D
−2.82%
1W
−6.59%
1M
−0.36%
3M
−8.29%
6M
−4.45%
1Y
−19.42%
YTD
−7.47%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 97 | 105 | 83 | 98 | 123 | 117 | 94 | 72 | 98 | 78 | 90 | 77 | 87 | |
| YoY Sales growth | +2% | +15% | -7% | +22% | +27% | +12% | +14% | -27% | -21% | -33% | -4% | +7% | -11% | |
| Expenses | 75 | 92 | 74 | 89 | 94 | 100 | 88 | 79 | 108 | 81 | 80 | 73 | 139 | |
| Operating Profit | 22 | 12 | 8 | 9 | 29 | 17 | 6 | -8 | -10 | -3 | 10 | 4 | -52 | |
| OPM % | 22% | 12% | 10% | 10% | 24% | 15% | 6% | -11% | -10% | -4.0% | 11% | 4.9% | -60% | |
| Other Income | 6 | 7 | 6 | 5 | 7 | 6 | 1 | 2 | 1 | 5 | 6 | 11 | 97 | |
| Interest | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | |
| Depreciation | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Profit before tax | 23 | 14 | 8 | 9 | 31 | 18 | 2 | -11 | -14 | -3 | 10 | 9 | 39 | |
| Tax % | 19% | 19% | 10% | 24% | 21% | 20% | 69% | -13% | 1% | 5% | 3% | 2% | 36% | |
| Net Profit | 18 | 11 | 7 | 7 | 25 | 14 | 1 | -10 | -14 | -4 | 10 | 9 | 25 | |
| EPS in Rs | 1.98 | 1.23 | 0.80 | 0.72 | 2.68 | 1.55 | 0.06 | -1.05 | -1.54 | -0.39 | 1.10 | 0.97 | 2.67 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −4.31% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 13 Aug '26 |
| Earnings day | −4.31% |
| +1 day | −3.49% |
| +5 days | −5.40% |
| +15 days | +14.94% |
| +30 days | +7.63% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202667.10%Promoter
Promoters67.10%
FIIs0.01%
DIIs0.01%
Public32.87%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Themis Medicare | ₹100.90 | — | 929 | 0.50% | 25 | −282.28% | 87 | −10.88% | 2.74% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts23
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Investor Presentation 15 NovResults: Financial Results For The Quarter And Half Year Ended 30.09.2026 14 Nov - Board approved unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.11.2026 14 Nov - Board approved unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.Update on board meeting 2 Nov - Board meeting rescheduled to November 14, 2026 to approve Q2 and half-year FY26 results.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Oct






